Share Price and Basic Stock Data
Last Updated: May 31, 2025, 8:25 pm
| PEG Ratio | 0.00 |
|---|
Competitors of Vivimed Labs Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 141 Cr. | 100 | 247/84.3 | 27.3 | 41.7 | 0.00 % | 12.9 % | 9.75 % | 10.0 |
| MPS Pharmaa Ltd | 5.48 Cr. | 2.87 | 4.33/2.50 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 2,663 Cr. | 244 | 390/192 | 50.6 | 20.5 | 0.27 % | 45.0 % | 33.8 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 41.4 Cr. | 55.8 | 94.9/44.5 | 8.73 | 0.00 % | 41.5 % | 14.4 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 37.7 Cr. | 25.7 | 29.1/13.1 | 37.0 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 18,565.29 Cr | 1,158.58 | 103.22 | 194.43 | 0.31% | 16.65% | 15.19% | 6.18 |
Quarterly Result
| Metric | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 56.52 | 61.13 | 50.11 | 44.22 | 55.74 | 37.03 | 35.35 | 33.64 | 41.46 | 38.62 | 29.37 | 24.77 | 36.51 |
| Expenses | 63.81 | 62.21 | 58.69 | 53.53 | 60.87 | 201.32 | 35.68 | 39.54 | 40.19 | 67.09 | 40.37 | 25.41 | 35.46 |
| Operating Profit | -7.29 | -1.08 | -8.58 | -9.31 | -5.13 | -164.29 | -0.33 | -5.90 | 1.27 | -28.47 | -11.00 | -0.64 | 1.05 |
| OPM % | -12.90% | -1.77% | -17.12% | -21.05% | -9.20% | -443.67% | -0.93% | -17.54% | 3.06% | -73.72% | -37.45% | -2.58% | 2.88% |
| Other Income | -0.36 | 0.57 | 0.08 | 0.15 | 0.05 | 0.68 | 0.11 | 2.20 | 0.04 | 7.63 | 0.06 | 0.03 | 0.07 |
| Interest | 11.58 | 10.06 | 9.31 | 8.85 | 9.22 | 8.52 | 10.66 | 11.89 | 13.21 | -33.33 | 0.30 | 0.43 | 0.48 |
| Depreciation | 4.45 | 4.95 | 4.45 | 4.02 | 4.02 | 95.92 | 4.70 | 4.70 | 4.70 | 5.84 | 4.01 | 4.10 | 6.62 |
| Profit before tax | -23.68 | -15.52 | -22.26 | -22.03 | -18.32 | -268.05 | -15.58 | -20.29 | -16.60 | 6.65 | -15.25 | -5.14 | -5.98 |
| Tax % | 0.00% | 18.17% | -0.22% | 0.00% | 0.00% | -0.77% | 0.00% | 0.00% | -3.31% | 20.90% | 0.00% | 0.00% | 0.00% |
| Net Profit | -23.68 | -18.33 | -22.20 | -22.03 | -18.31 | -265.99 | -15.58 | -20.30 | -16.05 | 5.26 | -15.25 | -5.14 | -5.98 |
| EPS in Rs | -2.86 | -2.21 | -2.68 | -2.66 | -2.21 | -32.08 | -1.88 | -2.45 | -1.94 | 0.63 | -1.84 | -0.62 | -0.72 |
Last Updated: March 4, 2025, 2:54 pm
Below is a detailed analysis of the quarterly data for Vivimed Labs Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:
- For Sales, as of Dec 2024, the value is 36.51 Cr.. The value appears strong and on an upward trend. It has increased from 24.77 Cr. (Sep 2024) to 36.51 Cr., marking an increase of 11.74 Cr..
- For Expenses, as of Dec 2024, the value is 35.46 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 25.41 Cr. (Sep 2024) to 35.46 Cr., marking an increase of 10.05 Cr..
- For Operating Profit, as of Dec 2024, the value is 1.05 Cr.. The value appears strong and on an upward trend. It has increased from -0.64 Cr. (Sep 2024) to 1.05 Cr., marking an increase of 1.69 Cr..
- For OPM %, as of Dec 2024, the value is 2.88%. The value appears strong and on an upward trend. It has increased from -2.58% (Sep 2024) to 2.88%, marking an increase of 5.46%.
- For Other Income, as of Dec 2024, the value is 0.07 Cr.. The value appears strong and on an upward trend. It has increased from 0.03 Cr. (Sep 2024) to 0.07 Cr., marking an increase of 0.04 Cr..
- For Interest, as of Dec 2024, the value is 0.48 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.43 Cr. (Sep 2024) to 0.48 Cr., marking an increase of 0.05 Cr..
- For Depreciation, as of Dec 2024, the value is 6.62 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4.10 Cr. (Sep 2024) to 6.62 Cr., marking an increase of 2.52 Cr..
- For Profit before tax, as of Dec 2024, the value is -5.98 Cr.. The value appears to be declining and may need further review. It has decreased from -5.14 Cr. (Sep 2024) to -5.98 Cr., marking a decrease of 0.84 Cr..
- For Tax %, as of Dec 2024, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.00%.
- For Net Profit, as of Dec 2024, the value is -5.98 Cr.. The value appears to be declining and may need further review. It has decreased from -5.14 Cr. (Sep 2024) to -5.98 Cr., marking a decrease of 0.84 Cr..
- For EPS in Rs, as of Dec 2024, the value is -0.72. The value appears to be declining and may need further review. It has decreased from -0.62 (Sep 2024) to -0.72, marking a decrease of 0.10.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: June 16, 2025, 3:27 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,351 | 1,380 | 1,346 | 1,462 | 1,186 | 1,315 | 1,059 | 861 | 237 | 187 | 149 | 116 |
| Expenses | 1,139 | 1,156 | 1,111 | 1,057 | 971 | 1,135 | 1,049 | 830 | 245 | 374 | 176 | 129 |
| Operating Profit | 212 | 224 | 234 | 404 | 215 | 180 | 10 | 32 | -8 | -187 | -27 | -13 |
| OPM % | 16% | 16% | 17% | 28% | 18% | 14% | 1% | 4% | -3% | -100% | -18% | -11% |
| Other Income | 8 | 6 | 11 | 8 | 10 | 23 | 8 | 10 | 1 | 1 | 4 | 4 |
| Interest | 67 | 86 | 84 | 68 | 82 | 70 | 61 | 56 | 40 | 36 | 3 | 3 |
| Depreciation | 66 | 66 | 61 | 58 | 56 | 67 | 67 | 56 | 18 | 108 | 20 | 20 |
| Profit before tax | 87 | 78 | 100 | 286 | 86 | 66 | -109 | -70 | -65 | -331 | -46 | -32 |
| Tax % | 24% | 7% | 16% | 25% | 11% | 13% | -0% | 3% | 4% | -1% | -1% | 0% |
| Net Profit | 66 | 72 | 84 | 214 | 76 | 57 | -109 | -72 | -68 | -329 | -45 | -32 |
| EPS in Rs | 8.20 | 8.90 | 10.33 | 26.41 | 9.44 | 6.95 | -13.16 | -8.67 | -8.16 | -39.62 | -5.48 | -3.85 |
| Dividend Payout % | 7% | 0% | 0% | 2% | 4% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 9.09% | 16.67% | 154.76% | -64.49% | -25.00% | -291.23% | 33.94% | 5.56% | -383.82% | 86.32% | 28.89% |
| Change in YoY Net Profit Growth (%) | 0.00% | 7.58% | 138.10% | -219.25% | 39.49% | -266.23% | 325.17% | -28.39% | -389.38% | 470.15% | -57.43% |
Vivimed Labs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -22% |
| 5 Years: | -36% |
| 3 Years: | -21% |
| TTM: | -22% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 11% |
| 3 Years: | 15% |
| TTM: | 19% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -18% |
| 5 Years: | -18% |
| 3 Years: | -24% |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Last Updated: Unknown
No data available for the Balance Sheet data table.
Cash Flow
| Month | Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Financial Efficiency Indicators
| Month | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 121 | 101 | 94 | 87 | 88 | 50 | 85 | 99 | 86 | 46 | 134 | 150 |
| Inventory Days | 268 | 247 | 249 | 244 | 294 | 329 | 411 | 397 | 396 | 263 | 573 | 216 |
| Days Payable | 170 | 118 | 106 | 107 | 98 | 122 | 154 | 207 | 179 | 35 | 100 | 93 |
| Cash Conversion Cycle | 220 | 230 | 237 | 224 | 285 | 258 | 342 | 288 | 303 | 274 | 607 | 273 |
| Working Capital Days | 208 | 161 | 159 | 146 | 169 | 151 | 239 | 161 | 216 | 190 | 653 | 588 |
| ROCE % | 14% | 13% | 12% | 11% | 12% | 22% | 9% | 7% | -3% | -1% | -3% | -52% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | -3.85 | -5.48 | -39.62 | -8.16 | -8.67 |
| Diluted EPS (Rs.) | -3.74 | -5.32 | -39.62 | -7.92 | -8.42 |
| Cash EPS (Rs.) | -1.42 | -3.08 | -26.55 | -5.95 | -1.98 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | -4.24 | -5.24 | 0.17 | 39.35 | 47.47 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | -4.24 | -0.65 | 4.75 | 43.93 | 52.05 |
| Revenue From Operations / Share (Rs.) | 14.02 | 17.98 | 22.57 | 28.62 | 103.90 |
| PBDIT / Share (Rs.) | -1.05 | -2.13 | -22.47 | -0.81 | 4.77 |
| PBIT / Share (Rs.) | -3.49 | -4.53 | -35.55 | -3.02 | -1.93 |
| PBT / Share (Rs.) | -3.84 | -4.82 | -39.88 | -7.82 | -8.43 |
| Net Profit / Share (Rs.) | -3.85 | -5.48 | -39.62 | -8.16 | -8.67 |
| NP After MI And SOA / Share (Rs.) | -3.85 | -5.48 | -39.62 | -8.16 | -8.67 |
| PBDIT Margin (%) | -7.46 | -11.82 | -99.59 | -2.86 | 4.58 |
| PBIT Margin (%) | -24.85 | -25.19 | -157.53 | -10.56 | -1.85 |
| PBT Margin (%) | -27.39 | -26.82 | -176.72 | -27.32 | -8.10 |
| Net Profit Margin (%) | -27.48 | -30.48 | -175.59 | -28.50 | -8.34 |
| NP After MI And SOA Margin (%) | -27.48 | -30.48 | -175.59 | -28.50 | -8.34 |
| Return on Networth / Equity (%) | 0.00 | 0.00 | -23087.35 | -20.73 | -18.26 |
| Return on Capital Employeed (%) | -5.63 | -6.94 | -52.25 | -2.80 | -1.68 |
| Return On Assets (%) | -3.47 | -4.77 | -33.24 | -5.34 | -5.57 |
| Long Term Debt / Equity (X) | -1.81 | -1.46 | 43.79 | 0.18 | 0.14 |
| Total Debt / Equity (X) | -10.70 | -8.67 | 266.03 | 1.10 | 0.64 |
| Asset Turnover Ratio (%) | 0.12 | 0.15 | 0.16 | 0.18 | 0.12 |
| Current Ratio (X) | 0.80 | 0.83 | 0.78 | 1.36 | 1.55 |
| Quick Ratio (X) | 0.65 | 0.67 | 0.59 | 0.71 | 0.80 |
| Inventory Turnover Ratio (X) | 0.94 | 1.25 | 1.17 | 0.57 | 0.24 |
| Interest Coverage Ratio (X) | -2.94 | -7.25 | -5.19 | -0.17 | 0.73 |
| Interest Coverage Ratio (Post Tax) (X) | -9.85 | -15.29 | -8.15 | -0.70 | -0.33 |
| Enterprise Value (Cr.) | 0.00 | 0.00 | 430.11 | 471.51 | 378.03 |
| EV / Net Operating Revenue (X) | 0.00 | 0.00 | 2.30 | 1.99 | 0.43 |
| EV / EBITDA (X) | 0.00 | 0.00 | -2.31 | -69.44 | 9.57 |
| MarketCap / Net Operating Revenue (X) | 0.00 | 0.00 | 0.29 | 0.50 | 0.15 |
| Price / BV (X) | 0.00 | 0.00 | 38.87 | 0.36 | 0.33 |
| Price / Net Operating Revenue (X) | 0.00 | 0.00 | 0.29 | 0.50 | 0.15 |
| EarningsYield | 0.00 | 0.00 | -5.94 | -0.56 | -0.54 |
After reviewing the key financial ratios for Vivimed Labs Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -3.85. This value is below the healthy minimum of 5. It has increased from -5.48 (Mar 24) to -3.85, marking an increase of 1.63.
- For Diluted EPS (Rs.), as of Mar 25, the value is -3.74. This value is below the healthy minimum of 5. It has increased from -5.32 (Mar 24) to -3.74, marking an increase of 1.58.
- For Cash EPS (Rs.), as of Mar 25, the value is -1.42. This value is below the healthy minimum of 3. It has increased from -3.08 (Mar 24) to -1.42, marking an increase of 1.66.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -4.24. It has increased from -5.24 (Mar 24) to -4.24, marking an increase of 1.00.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -4.24. It has decreased from -0.65 (Mar 24) to -4.24, marking a decrease of 3.59.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 14.02. It has decreased from 17.98 (Mar 24) to 14.02, marking a decrease of 3.96.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -1.05. This value is below the healthy minimum of 2. It has increased from -2.13 (Mar 24) to -1.05, marking an increase of 1.08.
- For PBIT / Share (Rs.), as of Mar 25, the value is -3.49. This value is below the healthy minimum of 0. It has increased from -4.53 (Mar 24) to -3.49, marking an increase of 1.04.
- For PBT / Share (Rs.), as of Mar 25, the value is -3.84. This value is below the healthy minimum of 0. It has increased from -4.82 (Mar 24) to -3.84, marking an increase of 0.98.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -3.85. This value is below the healthy minimum of 2. It has increased from -5.48 (Mar 24) to -3.85, marking an increase of 1.63.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -3.85. This value is below the healthy minimum of 2. It has increased from -5.48 (Mar 24) to -3.85, marking an increase of 1.63.
- For PBDIT Margin (%), as of Mar 25, the value is -7.46. This value is below the healthy minimum of 10. It has increased from -11.82 (Mar 24) to -7.46, marking an increase of 4.36.
- For PBIT Margin (%), as of Mar 25, the value is -24.85. This value is below the healthy minimum of 10. It has increased from -25.19 (Mar 24) to -24.85, marking an increase of 0.34.
- For PBT Margin (%), as of Mar 25, the value is -27.39. This value is below the healthy minimum of 10. It has decreased from -26.82 (Mar 24) to -27.39, marking a decrease of 0.57.
- For Net Profit Margin (%), as of Mar 25, the value is -27.48. This value is below the healthy minimum of 5. It has increased from -30.48 (Mar 24) to -27.48, marking an increase of 3.00.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -27.48. This value is below the healthy minimum of 8. It has increased from -30.48 (Mar 24) to -27.48, marking an increase of 3.00.
- For Return on Networth / Equity (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 15. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Return on Capital Employeed (%), as of Mar 25, the value is -5.63. This value is below the healthy minimum of 10. It has increased from -6.94 (Mar 24) to -5.63, marking an increase of 1.31.
- For Return On Assets (%), as of Mar 25, the value is -3.47. This value is below the healthy minimum of 5. It has increased from -4.77 (Mar 24) to -3.47, marking an increase of 1.30.
- For Long Term Debt / Equity (X), as of Mar 25, the value is -1.81. This value is below the healthy minimum of 0.2. It has decreased from -1.46 (Mar 24) to -1.81, marking a decrease of 0.35.
- For Total Debt / Equity (X), as of Mar 25, the value is -10.70. This value is within the healthy range. It has decreased from -8.67 (Mar 24) to -10.70, marking a decrease of 2.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.12. It has decreased from 0.15 (Mar 24) to 0.12, marking a decrease of 0.03.
- For Current Ratio (X), as of Mar 25, the value is 0.80. This value is below the healthy minimum of 1.5. It has decreased from 0.83 (Mar 24) to 0.80, marking a decrease of 0.03.
- For Quick Ratio (X), as of Mar 25, the value is 0.65. This value is below the healthy minimum of 1. It has decreased from 0.67 (Mar 24) to 0.65, marking a decrease of 0.02.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.94. This value is below the healthy minimum of 4. It has decreased from 1.25 (Mar 24) to 0.94, marking a decrease of 0.31.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -2.94. This value is below the healthy minimum of 3. It has increased from -7.25 (Mar 24) to -2.94, marking an increase of 4.31.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -9.85. This value is below the healthy minimum of 3. It has increased from -15.29 (Mar 24) to -9.85, marking an increase of 5.44.
- For Enterprise Value (Cr.), as of Mar 25, the value is 0.00. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For EV / EBITDA (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.00.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Vivimed Labs Ltd:
- Net Profit Margin: -27.48%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -5.63% (Industry Average ROCE: 16.65%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0% (Industry Average ROE: 15.19%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -9.85
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.65
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 103.22)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: -10.7
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -27.48%
About the Company - Qualitative Analysis
No data availabale for About the Company
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Industry not found | Address not found | Contact not found |
Management Data not Available